Pharmacophore hybridization has recently been employed in the search for antimalarial lead compounds. This approach chemically links two pharmacophores, each with their own antimalarial activity and ideally with different modes of action, into a single hybrid molecule with the goal to improve therapeutic properties. In this paper we report the synthesis of novel 7-chloro-4-aminoquinoline:primary sulfonamide hybrid compounds. The chlorinated 4-aminoquinoline scaffold is the core structure of chloroquine, an established antimalarial drug, while the primary sulfonamide functional group has a proven track record of efficacy and safety in many clinically used drugs and was recently shown to exhibit some antimalarial activity. The activity of the hybrid compounds was determined against chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) Plasmodium falciparum strains. While the hybrid compounds had lower antimalarial activity when compared to chloroquine, they demonstrated a number of interesting structure-activity relationship (SAR) trends including the potential to overcome the resistance profile of chloroquine.
Introduction
Malaria remains a major global health issue that affects around 3.2 billion people and results in ~1 million deaths annually (1) . Efforts to control and eradicate malaria are hindered by the absence of a suitable vaccine and increasing resistance to clinically used drugs(2-7). To address the need for safe and effective new antimalarial drugs that overcome issues of crossresistance, numerous antimalarial drug discovery approaches are being actively pursued. These include whole-cell and target-based screening approaches, generation of pharmacokinetically optimized analogues of existing drugs, development of combination therapies, investigation of drug resistance reversers, and generation of hybrid compounds (8) . In the latter approach two antimalarial pharmacophores, preferably with different modes of action, are chemically combined. The aim is to generate hybrid compounds that have improved antimalarial activity, 3 stability, and/or solubility over the separate pharmacophores (9) . There are a number of potential advantages to the hybrid arrangement over combination therapies. A single agent ensures the same pharmacokinetics and avoids additional stress on clearance mechanisms that may accompany the administration of multiple agents. A number of antimalarial hybrids currently under investigation have focused on the antimalarial drug chloroquine, comprising a chlorinated 4-aminoquinoline scaffold, Figure 1 (10) (11) (12) (13) (14) (15) (16) (17) . Chloroquine accumulates in the food vacuole of the parasite and acts by interfering with the polymerisation of toxic heme moieties, the by-products of haemoglobin digestion in the intraerythrocytic cycle of the parasite (18) (19) (20) (21) .
Although Plasmodium falciparum, the most lethal human malaria parasite species, has developed resistance to chloroquine in most areas of the world, this drug remains effective for the treatment of other malaria parasite species such as Plasmodium vivax (8, 22) . In addition chloroquine is inexpensive, easily administered, and safe for use in infants and pregnancy.
These favourable biopharmaceutical properties make strategies aimed at overcoming issues of parasite resistance to this drug attractive. Hybrid compounds that retain the effective antimalarial attributes of chloroquine whilst overcoming the primary limitation (i.e. drug resistance) may therefore have potential therapeutic benefit. Recent examples that employ pharmacophore hybridization as an approach to antimalarial drug discovery include chloroquine-triazine hybrids, (23) (24) (25) chloroquine-pyrimidine hybrids, (26) trioxaquines (10, 27, 28) , the mefloquine-artesunate hybrid MEFAS (29) , the ferrocene-chloroquine hybrid, ferroquine (11, 12, 30) and others (14-16, 31, 32) , Figure 1 . The majority of these compounds have shown improved antimalarial activity over the parent compound when tested against drug resistant parasites (10-13, 15, 16, 27-29, 31, 32) . Furthermore several of these hybrid compounds have also shown comparable or better in vivo efficacy when tested in mouse malaria models (10-12, 27-29, 32) . Three hybrid compounds have advanced further along the malaria drug discovery pipeline with the mefloquine-artesunate hybrid MEFAS and the trioxaquine PA11103/SAR116242 currently undergoing pre-clinical development, while the organometallic drug candidate ferroquine is in phase II clinical trials (11, 28, 29) . Recently we reported the in vitro antimalarial activity of a series of primary sulfonamides.
These compounds had IC50s between 0.9 -4 µM and good selectivity for P. falciparum versus mammalian cells (selectivity index (SI) >50-100).(33) The IC50s of the most potent and selective of these compounds did not differ significantly between chloroquine-sensitive (3D7) and chloroquine resistant (Dd2) P. falciparum lines, indicating a different mode of action to chloroquine. It is widely reported that primary sulfonamides (R-SO2NH2) are excellent inhibitors of carbonic anhydrase (CA) zinc metalloenzymes (34) . There is substantial interest in disrupting CA activity in pathogens, including pathogenic bacteria (Brucella spp.,
Mycobacterium tuberculosis, Streptococcus pneumoniae, Salmonella enterica serovar
Typhimurium, Vibrio cholerae and Helicobacter pylori), pathogenic fungi (Candida albicans, C. glabrata, and Cryptococcus neoformans) and more recently the protozoan parasite Trypanosoma cruzi (35) (36) (37) (38) (39) (40) (41) . While the antimalarial target of these compounds is still under investigation in our lab, PfCA is a possible candidate. Given the early findings with primary sulfonamides and that hybrid drugs of chloroquine should ideally have an independent target to offset parasite resistance to chloroquine, here we investigate the combination 7-chloro-4-aminoquinolines and primary benzene sulfonamide hybrid compounds for altered antimalarial activity. In this study we have evaluated the in vitro antimalarial activity of several 7-chloro-4-aminoquinoline:primary sulfonamide hybrid compounds alongside analogues lacking a primary sulfonamide moiety as controls.
Methods and Materials

Chemistry General.
All starting materials and reagents were purchased from commercial suppliers. 3-Azidopropyl- The 100 mL reaction flask was sealed and heated for 17 h at 110 ºC. The reaction mixture was diluted with MeOH (10 mL), transferred to a round bottom flask and concentrated under reduced pressure. The crude product was dissolved in EtOAc (50 mL), washed with water (3 × 50 mL), and the aqueous fractions combined and extracted with EtOAc (2 × 50 mL -N-(3-(1-(4-aminosulfonylphenyl)-1H-1,2,3-triazol-4-yl) 
7-Chloro
7-Chloro-N-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine (12)
.
In vitro P. falciparum growth inhibition assay
P. falciparum growth inhibition assays were carried out using an isotopic [ 
Mammalian cell toxicity assays.
Neonatal foreskin fibroblast (NFF) cells were cultured in RPMI 1640 (Life Technologies, Inc., Rockville, MD) supplemented with 10% FCS (CSL Biosciences, Parkville, Victoria, Australia), 1% streptomycin (Life Technologies, Inc., Rockville, MD; complete medium) at 37 °C and 5% CO2. Cytotoxicity assays were carried out as previously described (47) .
Percentage inhibition of growth was compared to matched DMSO controls. IC50 values were calculated using linear interpolation of inhibition curves. The mean IC50 (±SD) is shown for two independent experiments, each carried out in triplicate.
Results and Discussion
Hybrid compound design.
The hybrid compounds (4, 5, 7, 8, 10 and 11) of this study comprise the 7-chloro-4-aminoquinoline scaffold of chloroquine and a primary benzene sulfonamide scaffold of CA inhibitors, Figure 2 . Hybrid compounds require a linker group to act as a spacer between the hybrid components. We selected the 1,2,3-triazole moiety as the linker group as this group is synthetically suited to covalently combining two scaffolds and is also stable to environments Low reaction yields for CuAAC reactions is attributed to an extensive purification protocol implemented to remove copper ions from the aminoquinoline-triazole products. 
In vitro antimalarial activity of hybrid compounds
The in vitro growth inhibitory activity of 7-chloro-4-aminoquinoline:primary sulfonamide hybrid compounds, and control analogues lacking a primary sulfonamide moiety, was tested against a drug-sensitive (3D7) and drug-resistant (Dd2) P. falciparum line. Line 3D7 is sensitive to chloroquine (IC50 0.02 µM) while line Dd2 is considered resistant to chloroquine (IC50 0.08 µM). The 3D7 and Dd2 IC50s for chloroquine are consistent with previous reports (52, 53) . Of the compounds tested, 6 (IC50 ~1 µM), 9 (IC50 ~0.2-0.3 µM) and 12 (IC50 ~0.6 µM) displayed the most potent inhibitory activity, however all were at least 10-fold less active than chloroquine alone (Table 1) . Notably, these compounds are the control analogues that do not contain a primary sulfonamide, suggesting that the sulfonamide moiety may reduce antimalarial potency when combined with the 7-chloro-4-aminoquinoline scaffold in hybrid compounds. Interestingly the resistance index (Ri), which is the ratio of the IC50s of the resistant line Dd2 to the sensitive line 3D7, for compounds 6, 9 and 12 was ≤ 1.4. This Ri value is substantially lower than that obtained for chloroquine (Ri = 4.3), indicating that the addition of the phenyl-1,2,3-triazole to the aminoquinoline scaffold overcomes the change in sensitivity seen for these two lines when exposed only to chloroquine.
Of the hybrid compounds with a primary sulfonamide group either meta-or para-to the 1,2,3-triazole group, the position of the primary sulfonamide substituent had an effect on antimalarial potency. The meta-regiosomers (5, 8 and 11) were more potent than the corresponding pararegiosomers (4, 7 and 10) against both sensitive and resistant parasite lines. This finding suggests that the sulfonamide group has the potential to be optimized further for antimalarial potency using this hybrid compound approach. The meta-sulfonamide 11 was the most potent sulfonamide, with similar activity against the drug sensitive and resistant P. falciparum lines (IC50 ~2 µM; Ri = 0.8). In contrast, compound 10, the para-regioisomer of 11, had poorer activity for the Dd2 line resulting in a higher Ri (Ri = 3.7) than 10, interestingly this Ri value is similar to that for chloroquine (Ri = 4.3). The structure-activity relationship between the metaand para-sulfonamide regioisomers and the resistance index is reversed for regioisomers 4 and In order to examine the selectivity of 7-chloro-4-aminoquinoline:primary sulfonamide hybrids and controls for P. falciparum parasites versus normal mammalian cells, in vitro cytotoxicity assays were carried out with neonatal foreskin fibroblast (NFF) cells and the results compared to that obtained for chloroquine. In agreement with previous reports by ourselves and others, chloroquine has a high selectivity index (SI) for parasites versus this normal mammalian cell line (SI = 301-1220) (47, 54, 55) . Of the 7-chloro-4-aminoquinoline:primary sulfonamide hybrid and control analogues, control compound 9, had the highest SI (>833) and was also the most potent in terms of its activity P. falciparum (IC50 0.2-0.3 µM; Table 1 ). The other control compounds, 6 and 12, also had good selectivity (SI >227 and 104, respectively) for parasites versus NFF cells (Table 1 ). All primary sulfonamide hybrids were relatively non-toxic to NFF cells with no inhibition observed at the highest concentration tested (250 µM).
Conclusion
In summary we have demonstrated the utility of CuAAC for the reliable synthesis of hybrid compounds that combine two antimalarial pharmacophores. Although the panel of 7-chloro-4-aminoquinoline:primary sulfonamide hybrid compounds 4, 5, 7, 8, 10 and 11 all had reduced antimalarial activity when compared to chloroquine, they did however demonstrate the potential to overcome the resistance profile of chloroquine. This SAR suggests that the hybrid compounds may act differently than chloroquine against the lines tested. An additional finding was that the meta-sulfonamides (5, 8 and 11) were more potent than their matched parasulfonamides (4, 7 and 10, respectively) against both sensitive and resistant parasite lines.
Given that these hybrid compounds are regiosomers they likely share the same physicochemical properties, indicating that the primary sulfonamide group may have potential to be further optimized for antimalarial activity through structural modifications of the hybrid compounds. The most potent compound examined (9) also had the best selectivity (SI >833) for the parasite versus a normal mammalian cell line. The potency and selectivity of compound Calculated Log P (cLog P) values using CS ChemDraw Ultra.
